Clinical Trials List
2020-10-07 - 2022-06-30
Phase II
Recruiting2
Terminated3
A Randomized, Multicenter, Open-Label, Two-Arm, Phase II, Neoadjuvant Study Evaluating the Efficacy, Safety, and Pharmacokinetics of GDC-9545 Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer
-
Trial Applicant
QPS
-
Sponsor
F. Hoffmann-La Roche Ltd
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Chun-Yu Liu 無
- Yi-Fang Tsai 無
- Ta-Chung Chao 無
- 賴亦貞 無
- 邱仁輝 無
- Chi-Cheng Huang 無
- 馮晉榮 無
- 林燕淑 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 張端瑩 無
- 郭文宏 無
- 羅喬 無
- MING-YANG WANG 無
- 李宜軒 無
- 蔡立威 無
- YEN-SHEN LU 無
- 林季宏 無
- Wei-Wu Chen 無
- 張允中 無
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- 甘蓉瑜 無
- Chung-Liang Li 無
- Fang-Ming Chen 無
- 巫承哲 無
- Chieh-Han Chuang 無
- Shen Liang Shih 無
- 高捷妮 無
- Fu Ouyang 無
- Junping Shiau Shiau 無
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Objectives
Test Drug
Palbociclib
Anastrozole
Active Ingredient
Palbociclib
Anastrozole
Dosage Form
capsule
tablet
Dosage
75/100/125 mg capsule
1mg film-coated tablet
Endpoints
Inclution Criteria
Histologically confirmed operable or inoperable invasive breast carcinoma
Candidate for neoadjuvant treatment and considered appropriate for endocrine therapy
Willingness to undergo breast surgery after neoadjuvant treatment and to provide three mandatory tumor samples
Documented estrogen receptor (ER)-positive tumor in accordance to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (Allison et al.2020), assessed locally and defined as ≥1% of tumor cells stained positive on the basis of the most recent tumor biopsy
Documented progesterone receptor status (positive or negative) as per local assessment
Documented human epidermal growth factor receptor-2 (HER2)-negative tumor in accordance to 2018 ASCO/CAP guidelines (Wolff et al. 2018), assessed locally on the most recent tumor biopsy
Ki67 score ≥5% analyzed centrally or locally
Eastern Cooperative Oncology Group Performance Status 0-1
Adequate organ function
Exclusion Criteria
Inflammatory breast cancer (cT4d)
Bilateral invasive breast cancer
History of invasive breast cancer, ductal carcinoma in situ or lobular carcinoma in situ and other malignancy within 5 years prior to screening
Previous systemic or local treatment for the primary breast cancer currently under investigation
History of any prior treatment with aromatase inhibitors (AIs), tamoxifen, selective estrogen receptor down regulator, or cyclin-dependent kinase 4 and 6 inhibitors
Major surgery within 4 weeks prior to randomization
Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including hepatitis
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
History of allergy to anastrozole, or palbociclib or any of its excipients
Known issues with swallowing oral medication
History of documented hemorrhagic diathesis, coagulopathy, or thromboembolism
Active cardiac disease or history of cardiac dysfunction
Current treatment with medications that are well known to prolong the QT interval
Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or major upper gastrointestinal surgery including gastric resection
Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drug elimination half-lives prior to randomization
Known HIV infection
Serious infection requiring oral or IV antibiotics, or other clinically significant infection within 14 days prior to screening
Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
The Estimated Number of Participants
-
Taiwan
14 participants
-
Global
215 participants
